Novartis puts pressure on Germany's retrospective AMNOG reviews
This article was originally published in Scrip
Companies sweating over whether their older products will be called up for retrospective review under Germany's tough AMNOG health technology appraisal process are holding their breath. A court has temporarily halted the back assessment of gliptins already on the market and is deciding whether to uphold a complaint about the process from Novartis. A ruling in favor of Novartis could delay more retrospective assessments, or even foil them altogether.